Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Impacts of Posttransplant Cyclophosphamide Dose on Graft-versus-Leukemia Effects via HLA-B Leader in HLA-Haploidentical Peripheral Blood Stem Cell Transplantation.

Acta haematologica - 1 Jan 2024

Moriguchi Makoto, Ido Kentaro, Okamura Hiroshi, Nakamae Mika, Sakatoku Kazuki, Makuuchi Yosuke, Kuno Masatomo, Takakuwa Teruhito, Hirose Asao, Nishimoto Mitsutaka, Nakashima Yasuhiro, Koh Hideo, Hino Masayuki, Nakamae Hirohisa

Abstract excerpt

INTRODUCTION: The graft-versus-leukemia effect of HLA-B leader dimorphism, i.e., methionine (M) or threonine (T) at position -21 of the leader sequence, has been observed in HLA-haploidentical hematopoietic cell transplantation with posttransplant cyclophosphamide (PTCy-haplo). However, the biological mechanism has been unclear, and the contributions of HLA-B leader genotype to risk reduction of relapse might be...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adolescent
Share to Aged

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cyclophosphamide

Share to Genotype

Share to HLA-B Antigens

Share to Young Adult

Source

Identifiers

PMID: 38432202
DOI: 10.1159/000538078

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impacts of Posttransplant Cyclophosphamide Dose on Graft-versus-Leukemia Effects via HLA-B Leader in HLA-Haploidentical Peripheral Blood Stem Cell Transplantation.PMID 38432202Read ↗

Lineage-Specific Relapse Prediction After Haploidentical Transplantation With Post-Transplant Cyclophosphamide Based on Recipient HLA-B-Leader Genotype and HLA-C-Group KIR Ligand.Semantic proximity Read ↗

Intermediate-dose posttransplantation cyclophosphamide for myeloablative HLA-haploidentical bone marrow transplantationSemantic proximity Read ↗

Effect of Donor NKG2D Polymorphism on Relapse after Haploidentical Transplantation with Post-Transplantation Cyclophosphamide.Semantic proximity Read ↗

The impact of donor-specific anti-human leukocyte antigen antibodies in salvage haploidentical hematopoietic cell transplantation with posttransplant cyclophosphamide in patients with nonmalignant disorders.Semantic proximity Read ↗

Revised HLA-DP TCE-Core Permissiveness Model Better Defines Relapse Risk and Survival following Haploidentical Transplant.Semantic proximity Read ↗

HLA-B Leader and Survivorship after HLA-Mismatched Unrelated Donor TransplantationSemantic proximity Read ↗

Use of the HLA-B leader to optimize cord blood transplantationSemantic proximity Read ↗

Selecting the Best Donor for Haploidentical Transplant: Impact of HLA, Killer Cell Immunoglobulin-Like Receptor Genotyping, and Other Clinical VariablesSemantic proximity Read ↗

Posttransplant cyclophosphamide in unrelated and related peripheral blood stem cell transplantation from HLA-matched and 1 allele mismatched donor.Semantic proximity Read ↗

Donor lymphocyte infusion for prevention of relapse after unmanipulated haploidentical PBSCT for very high-risk hematologic malignancies.Semantic proximity Read ↗

Posttransplant cyclophosphamide in HLA-matched and 1-2 allele mismatched peripheral blood stem cell transplantationSemantic proximity Read ↗

National Marrow Donor Program–Sponsored Multicenter, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation Using Post-Transplant CyclophosphamideSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.